Agios Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) is a commercial-stage biopharmaceutical company focused on the discovery and development of small-molecule medicines for patients with rare diseases, with a core specialization in classical hematology and cellular metabolism. The company's lead commercial product is mitapivat, an oral pyruvate kinase (PK) activator marketed under two brand names: PYRUKYND, approved for hemolytic anemia in adults with PK deficiency, and AQVESME, approved in December 2025 for anemia in adults with alpha- or beta-thalassemia. Agios is actively seeking to expand mitapivat's label into sickle cell disease (SCD). Additionally, the company's pipeline includes tebapivat (a next-generation PK activator), AG-181 (a phenylalanine hydroxylase stabilizer for phenylketonuria), AG-236 (an siRNA targeting TMPRSS6 for polycythemia vera), and cevidoplenib (a next-generation SYK inhibitor for immune thrombocytopenia).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Executing a high-impact commercial launch of AQVESME (mitapivat) in the United States for the treatment of anemia in adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia [1.1.2].
Expected impact: Drives near-term product revenue growth and establishes market presence in rare hematology.
Advancing the clinical development of PK activators (mitapivat and tebapivat) into high-value indications such as sickle cell disease and pediatric PK deficiency.
Expected impact: Diversifies the rare disease pipeline and extends the commercial lifecycle of the PK activator class.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Diversifies Agios' rare hematology portfolio by expanding into immune thrombocytopenia (ITP) with cevidoplenib, a next-generation oral spleen tyrosine kinase (SYK) inhibitor [2.2.1].
Terms: $25.0 million upfront payment, up to $140.0 million in development and regulatory milestones across up to three indications in the U.S. and Europe, up to $500.0 million in commercial milestones, and tiered royalties ranging from high single digits to mid-teens on future net sales.